AAPL 258.2 1.1478% MSFT 439.33 0.9374% NVDA 140.22 0.3938% GOOGL 196.11 0.7604% GOOG 197.57 0.8062% AMZN 229.05 1.7729% META 607.75 1.317% AVGO 239.68 3.1547% TSLA 462.28 7.3572% TSM 206.33 -0.4967% LLY 795.67 -0.0766% V 320.65 1.0813% JPM 242.31 1.6444% UNH 506.1 -0.0474% NVO 87.37 -1.5105% WMT 92.68 2.5789% LVMUY 132.15 0.1516% XOM 106.4 0.0941% LVMHF 655.0 -0.2543% MA 535.71 1.2761%
Last update at 2024-12-24T14:30:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 56.17M | 86.64M | 12.72M | 90.27M | 96.92M |
| Minority interest | -0.69700M | -1.66200M | 4.68M | 4.59M | -0.06900M |
| Net income | 42.51M | 63.99M | 6.21M | 66.04M | 79.75M |
| Selling general administrative | 338.58M | 328.03M | 306.95M | 301.50M | 272.43M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 439.75M | 455.39M | 391.24M | 438.65M | 386.80M |
| Reconciled depreciation | 49.37M | 51.64M | 64.70M | 43.56M | 28.39M |
| Ebit | 67.14M | 95.62M | 53.27M | 99.23M | 90.52M |
| Ebitda | 116.74M | 148.08M | 87.03M | 142.16M | 129.07M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 67.14M | 95.62M | 53.27M | 105.83M | 83.02M |
| Other operating expenses | - | - | - | - | 0.00000M |
| Interest expense | 11.20M | 9.80M | 9.61M | 8.33M | 3.76M |
| Tax provision | 12.96M | 20.98M | 4.80M | 21.39M | 17.10M |
| Interest income | 0.78M | 0.17M | 0.46M | 1.02M | 0.36M |
| Net interest income | -11.64100M | -12.18600M | -9.97800M | -8.98200M | -4.35400M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 12.96M | 20.98M | 4.80M | 21.39M | 17.10M |
| Total revenue | 718.65M | 718.67M | 629.50M | 686.26M | 612.88M |
| Total operating expenses | 651.51M | 623.04M | 576.24M | 580.44M | 529.86M |
| Cost of revenue | 278.90M | 263.28M | 238.27M | 247.61M | 226.07M |
| Total other income expense net | - | - | - | -15.55900M | 6.41M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 43.21M | 65.66M | 7.92M | 68.87M | 79.82M |
| Net income applicable to common shares | 42.51M | 63.99M | 6.21M | 66.04M | 79.75M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1325.36M | 1246.91M | 1214.33M | 1090.67M | 913.55M |
| Intangible assets | 62.00M | 58.84M | 59.50M | 62.66M | 49.11M |
| Earning assets | - | - | - | - | - |
| Other current assets | 8.86M | 8.35M | 6.02M | 5.74M | 4.04M |
| Total liab | 689.85M | 620.32M | 637.14M | 521.72M | 376.02M |
| Total stockholder equity | 635.70M | 621.59M | 572.51M | 564.37M | 534.46M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 58.17M | 30.99M | 31.20M | 32.22M | 17.20M |
| Common stock | 4.78M | 4.79M | 4.79M | 4.79M | 4.81M |
| Capital stock | 4.78M | 4.79M | 4.79M | 4.79M | 93.77M |
| Retained earnings | 641.23M | 593.20M | 530.42M | 534.93M | 488.36M |
| Other liab | 58.76M | 53.00M | 41.84M | 43.70M | 36.41M |
| Good will | 680.40M | 644.15M | 612.19M | 521.05M | 500.84M |
| Other assets | 41.04M | 29.97M | 31.45M | 30.08M | 20.57M |
| Cash | 76.63M | 85.20M | 102.36M | 58.61M | 55.71M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 237.01M | 186.46M | 147.31M | 141.08M | 117.56M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 263.15M | 223.04M | 255.16M | 192.51M | 179.78M |
| Short term debt | - | - | - | 7.19M | 0.00000M |
| Short long term debt | 62.07M | 46.04M | 17.55M | 7.19M | 13.43M |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | -71.73500M | -47.18400M | -32.78100M | -48.37500M | -47.66300M |
| Property plant equipment | 179.32M | 182.08M | 171.38M | 163.41M | 63.03M |
| Total current assets | 348.85M | 318.23M | 326.46M | 307.38M | 274.01M |
| Long term investments | - | - | - | 7.91M | 7.68M |
| Net tangible assets | -106.69900M | -81.40300M | -99.18100M | -19.33800M | -15.49100M |
| Short term investments | - | - | - | - | 0.00000M |
| Net receivables | 116.74M | 102.77M | 112.00M | 116.26M | 107.75M |
| Long term debt | 277.71M | 262.19M | 339.98M | 243.93M | 222.05M |
| Inventory | 132.13M | 103.98M | 93.23M | 112.01M | 95.86M |
| Accounts payable | 28.65M | 26.72M | 20.02M | 26.68M | 28.14M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | - | - | - | - | 0.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 0.00100M | - | - | -0.00100M | -0.00100M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 976.51M | 928.68M | 887.87M | 783.29M | 639.55M |
| Capital lease obligations | 141.15M | 139.92M | 125.87M | 109.10M | 0.00000M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -66.26100M | -59.44700M | -106.44900M | -62.36400M | -92.14300M |
| Change to liabilities | 10.94M | 7.76M | -7.90500M | 0.90M | -1.64300M |
| Total cashflows from investing activities | -66.26100M | -59.44700M | -106.44900M | -62.36400M | -92.14300M |
| Net borrowings | 14.36M | -49.74300M | 67.67M | 1.94M | 73.23M |
| Total cash from financing activities | 3.79M | -51.07300M | 51.86M | -29.29800M | 44.37M |
| Change to operating activities | 11.58M | 11.58M | 11.58M | 11.58M | 1.97M |
| Net income | 42.51M | 63.99M | 6.21M | 66.04M | 79.75M |
| Change in cash | -8.56600M | -17.16600M | 43.75M | 2.90M | 18.43M |
| Begin period cash flow | 85.20M | 102.36M | 58.61M | 55.71M | 37.27M |
| End period cash flow | 76.63M | 85.20M | 102.36M | 58.61M | 55.71M |
| Total cash from operating activities | 60.77M | 100.53M | 92.24M | 95.28M | 69.44M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 43.49M | 45.54M | 42.20M | 38.27M | 19.06M |
| Other cashflows from investing activities | 1.47M | 1.18M | -6.14100M | -0.06700M | 4.43M |
| Dividends paid | - | - | 9.28M | 9.06M | 9.18M |
| Change to inventory | -28.62000M | -15.78300M | 12.75M | -14.66700M | -13.91000M |
| Change to account receivables | -13.45700M | -13.18400M | 18.45M | -11.22600M | -1.77600M |
| Sale purchase of stock | -9.94100M | - | - | - | -19.25600M |
| Other cashflows from financing activities | -0.63000M | -1.33000M | -2.59400M | -1.57600M | -0.42200M |
| Change to netincome | -11.55500M | -11.55500M | 14.61M | 10.68M | -19.09600M |
| Capital expenditures | 16.55M | 16.96M | 13.77M | 19.89M | 21.89M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -19.55200M | -21.20900M | 23.29M | -21.60900M | -15.36400M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | - | - | - | - | - |
| Free cash flow | 34.83M | 73.84M | 68.22M | 63.43M | 38.58M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OSSUY Össur hf |
- -% | 4.05 | 31.15 | - | 2.22 | 2.52 | 2.73 | 15.50 |
| ABT Abbott Laboratories |
0.45 0.39% | 114.76 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
4.29 1.17% | 370.78 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.14 0.17% | 81.54 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
1.21 1.35% | 91.07 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Össur hf., together with its subsidiaries, engages in the design, development, production, and sale of non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company operates through two segments: Prosthetics and Bracing & Supports. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated with sensors, computing power, internal intelligence, and actuators for amputees. The Bracing & Supports segment provides bracing and supports products, such as supporting devices for spinal, knee, hip, foot, ankle, and hands that are primarily used to support joints and other body parts for therapeutic and preventative purposes; and injury solutions to enhance the healing process of fractures and ligament injuries. It serves specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgery centers. The company sells its products through its direct sales networks and distributors. Össur hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Össur hf. is a subsidiary of William Demant Invest A/S.
Grjothals 1-5, Reykjavik, Iceland
| Name | Title | Year Born |
|---|---|---|
| Mr. Sveinn Solvason | Pres & CEO | 1978 |
| Mr. Ossur Kristinsson | Founder | 1943 |
| Ms. Gudny Arna Sveinsdottir | Chief Financial Officer | 1966 |
| Mr. Egill Jonsson | Exec. VP of Manufacturing & Operations | 1957 |
| Edda Lara Luovigsdottir | Investor Relations Director | NA |
| Ms. Sigurborg Arnarsdottir | Compliance Officer | NA |
| Ms. Margret Lara Fridriksdottir | Exec. VP of HR & Corp. Strategy | 1978 |
| Mr. Olafur Gylfason | Exec. VP of Prosthetics & Europe/Emerging Markets | 1969 |
| Mr. Gudjon G. Karason | Exec. VP of Clinics | 1969 |
| Mr. Christian Robinson | Exec. VP of Bracing & Supports and Americas | 1982 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...